Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Free Cash Flow data on file, last reported at -$51.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 30.55% year-over-year to -$51.1 million in Q1 2026; TTM through Mar 2026 was -$213.4 million, a 21.73% increase from a year earlier, with the FY2025 full-year figure at -$235.9 million, up 6.08% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$51.1 million, down from -$44.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for RLAY reached as high as -$44.9 million in Q4 2025 and fell as low as -$89.3 million in Q4 2023.
• Historically, Free Cash Flow has averaged -$63.6 million across 5 years, with a median of -$62.1 million in 2025.
• Across the five-year window, Free Cash Flow sank 212.57% in 2022 and jumped 35.2% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$59.4 million in 2022, then tumbled by 50.36% to -$89.3 million in 2023, then soared by 35.2% to -$57.9 million in 2024, then grew by 22.47% to -$44.9 million in 2025, then slipped by 13.92% to -$51.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$51.1 million in Q1 2026, -$44.9 million in Q4 2025, and -$62.1 million in Q3 2025.